189 related articles for article (PubMed ID: 19615804)
1. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
[TBL] [Abstract][Full Text] [Related]
3. Oral adsorbents for preventing or delaying the progression of chronic kidney disease.
Wu HM; Sun HJ; Wang F; Yang M; Dong BR; Liu GJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007861. PubMed ID: 25317905
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease.
Takahashi T; Reed SD; Schulman KA
Nephrology (Carlton); 2008 Oct; 13(5):419-27. PubMed ID: 18518936
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF.
Sanaka T; Fujimoto K; Niwayama J; Nishimura H; Naito T; Higuchi C; Akizawa T; Koide K; Koshikawa S
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S35-7. PubMed ID: 12612949
[TBL] [Abstract][Full Text] [Related]
6. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
[TBL] [Abstract][Full Text] [Related]
7. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
8. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD).
Morita S; Fukuhara S; Akizawa T; Asano Y; Kurokawa K
Clin Exp Nephrol; 2005 Sep; 9(3):219-27. PubMed ID: 16189630
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
Schulman G; Agarwal R; Acharya M; Berl T; Blumenthal S; Kopyt N
Am J Kidney Dis; 2006 Apr; 47(4):565-77. PubMed ID: 16564934
[TBL] [Abstract][Full Text] [Related]
10. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH; Hou FF; Zhang X; Liu QF
Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.
Cha RH; Kang SW; Park CW; Cha DR; Na KY; Kim SG; Yoon SA; Han SY; Chang JH; Park SK; Lim CS; Kim YS
Clin J Am Soc Nephrol; 2016 Apr; 11(4):559-67. PubMed ID: 26912554
[TBL] [Abstract][Full Text] [Related]
12. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases.
Ueda H; Shibahara N; Takagi S; Inoue T; Katsuoka Y
Ther Apher Dial; 2007 Jun; 11(3):189-95. PubMed ID: 17498000
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
Sanaka T; Akizawa T; Koide K; Koshikawa S
Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
[TBL] [Abstract][Full Text] [Related]
14. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
Takahashi N; Kawaguchi T; Suzuki T
Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
[TBL] [Abstract][Full Text] [Related]
16. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.
Fujii H; Nishijima F; Goto S; Sugano M; Yamato H; Kitazawa R; Kitazawa S; Fukagawa M
Nephrol Dial Transplant; 2009 Jul; 24(7):2089-95. PubMed ID: 19188341
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure.
Yorioka N; Ito T; Masaki T; Ogata S; Asakimori Y; Tanji C; Kyuden Y; Komiya Y; Kumagai J; Taniguchi Y; Kohno N
J Int Med Res; 2002; 30(5):467-75. PubMed ID: 12449515
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function.
Shoji T; Wada A; Inoue K; Hayashi D; Tomida K; Furumatsu Y; Kaneko T; Okada N; Fukuhara Y; Imai E; Tsubakihara Y
Nephron Clin Pract; 2007; 105(3):c99-107. PubMed ID: 17179734
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure.
Owada A; Shiigai T
Am J Nephrol; 1996; 16(2):124-7. PubMed ID: 8919228
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study.
Owada A; Nakao M; Koike J; Ujiie K; Tomita K; Shiigai T
Kidney Int Suppl; 1997 Dec; 63():S188-90. PubMed ID: 9407455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
